风湿免疫科指南

订阅

MedSci主页 / 所有栏目 / 风湿免疫科指南

口服免疫治疗用于食物过敏的共识报告2019

欧洲变应性反应与临床免疫学会 . 2020 Jun 4;S0091-6749(20)30747-8.

口服免疫治疗

食物过敏是一个主要的健康问题，影响着发达国家5-10%的人口，其中估计有3200万美国人。尽管患有食物过敏症的患者人数众多，但直到2020年1月底，美国食品和药物管理局（FDA）还没有批准任何治疗食物

中文标题：

口服免疫治疗用于食物过敏的共识报告2019

英文标题：

Consensus Report From the Food Allergy Research and Education (FARE) 2019 Oral Immunotherapy for Food Allergy Summit

发布机构：

欧洲变应性反应与临床免疫学会

发布日期：

简要介绍：

食物过敏是一个主要的健康问题，影响着发达国家5-10%的人口，其中估计有3200万美国人。尽管患有食物过敏症的患者人数众多，但直到2020年1月底，美国食品和药物管理局（FDA）还没有批准任何治疗食物过敏症的方法。唯一的选择是避免食物过敏原的诱发因素和过敏反应的急性处理。有相当多的数据支持口服免疫疗法(OIT)作为一种有前途的新型治疗方案，包括现在FDA批准的花生OIT产品Palforzia。然而，OIT的长期生活质量改善数据各不相同，这取决于用于分析的措施。像许多疗法一样，OIT并非没有潜在的危害，和负担，食品OIT的患者特异性风险收益比的评估对临床医生和患者都产生了挑战，有许多未解的问题。食物过敏研究与教育（FARE）于2019年11月6日仿照欧洲过敏与临床免疫学学会（EAACI）和美国过敏、哮喘与免疫学学会（AAAAI）之间的PRACTALL会议组织了食物过敏口服免疫疗法峰会，以解决这些关键问题。医疗保健提供者、患者代表、研究人员、监管人员和食物过敏倡导者聚集在一起，讨论OIT，并确定共同点的领域以及现有研究中的差距和不确定和不同意的领域。本文的目的是总结讨论情况，促进临床医生和患者之间的合作，以帮助他们分别就提供和接受OIT作为治疗方案做出更明智的决定。

相关资料下载：
[AttachmentFileName(sort=1, fileName=xu2020.pdf)] GetToolGuiderByIdResponse(projectId=1, id=068441c001919e50, title=口服免疫治疗用于食物过敏的共识报告2019, enTitle=Consensus Report From the Food Allergy Research and Education (FARE) 2019 Oral Immunotherapy for Food Allergy Summit, guiderFrom= . 2020 Jun 4;S0091-6749(20)30747-8., authorId=0, author=, summary=食物过敏是一个主要的健康问题，影响着发达国家5-10%的人口，其中估计有3200万美国人。尽管患有食物过敏症的患者人数众多，但直到2020年1月底，美国食品和药物管理局（FDA）还没有批准任何治疗食物, cover=, journalId=0, articlesId=null, associationId=615, associationName=欧洲变应性反应与临床免疫学会, associationIntro=EAACI是一个集临床医生、科研人员及过敏性疾病专家于一体的协会组织，致力于改善受过敏性疾病困扰的患者健康。该协会目前拥有超过6,800名个人成员及41个欧洲国家社团，是欧洲过敏性疾病所有方面知识的主要来源。, copyright=0, guiderPublishedTime=null, originalUrl=, linkOutUrl=, content=<p>食物过敏是一个主要的健康问题，影响着发达国家5-10%的人口，其中估计有3200万美国人。尽管患有食物过敏症的患者人数众多，但直到2020年1月底，美国食品和药物管理局（FDA）还没有批准任何治疗食物过敏症的方法。唯一的选择是避免食物过敏原的诱发因素和过敏反应的急性处理。有相当多的数据支持口服免疫疗法(OIT)作为一种有前途的新型治疗方案，包括现在FDA批准的花生OIT产品Palforzia。然而，OIT的长期生活质量改善数据各不相同，这取决于用于分析的措施。像许多疗法一样，OIT并非没有潜在的危害，和负担，食品OIT的患者特异性风险收益比的评估对临床医生和患者都产生了挑战，有许多未解的问题。食物过敏研究与教育（FARE）于2019年11月6日仿照欧洲过敏与临床免疫学学会（EAACI）和美国过敏、哮喘与免疫学学会（AAAAI）之间的PRACTALL会议组织了食物过敏口服免疫疗法峰会，以解决这些关键问题。医疗保健提供者、患者代表、研究人员、监管人员和食物过敏倡导者聚集在一起，讨论OIT，并确定共同点的领域以及现有研究中的差距和不确定和不同意的领域。本文的目的是总结讨论情况，促进临床医生和患者之间的合作，以帮助他们分别就提供和接受OIT作为治疗方案做出更明智的决定。</p>, tagList=[TagDto(tagId=104190, tagName=口服免疫治疗)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=34, categoryName=全科医学, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=11, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5029, appHits=114, showAppHits=0, pcHits=701, showPcHits=4915, likes=4, shares=7, comments=9, approvalStatus=1, publishedTime=Sun Jun 14 08:04:14 CST 2020, publishedTimeString=null, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Sun Jun 14 08:04:07 CST 2020, updatedBy=4754896, updatedName=fbzhang, updatedTime=Fri Jan 05 11:48:04 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=xu2020.pdf)])
xu2020.pdf
下载请点击：
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1202660, encodeId=0f5b120266003, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Tue Mar 15 07:46:43 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182982, encodeId=b857118298203, content=口服免疫是个难题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be4f5437570, createdName=ms5000001146316601, createdTime=Mon Jan 10 22:18:22 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977024, encodeId=181a9e702476, content=快快快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5aec5112847, createdName=1461bde6m98暂无昵称, createdTime=Sat Jun 26 10:34:46 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967851, encodeId=95b796e85131, content=口服免疫疗法, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqhOK9Hy7pNdYtJHcetpYCa3iaoZ3lbGBPI4cg4t02cSn4vs01p4Ab2WRy1SFMRQ8fb26KlLia1TT9g/132, createdBy=c3de5238591, createdName=丁丁8399, createdTime=Sat May 22 23:47:22 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964247, encodeId=3fd196424e63, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a671610372, createdName=Sarinai, createdTime=Mon May 10 11:06:46 CST 2021, time=2021-05-10, status=1, ipAttribution=)]
    2022-03-15 胡国宏

    #学习#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1202660, encodeId=0f5b120266003, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Tue Mar 15 07:46:43 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182982, encodeId=b857118298203, content=口服免疫是个难题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be4f5437570, createdName=ms5000001146316601, createdTime=Mon Jan 10 22:18:22 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977024, encodeId=181a9e702476, content=快快快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5aec5112847, createdName=1461bde6m98暂无昵称, createdTime=Sat Jun 26 10:34:46 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967851, encodeId=95b796e85131, content=口服免疫疗法, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqhOK9Hy7pNdYtJHcetpYCa3iaoZ3lbGBPI4cg4t02cSn4vs01p4Ab2WRy1SFMRQ8fb26KlLia1TT9g/132, createdBy=c3de5238591, createdName=丁丁8399, createdTime=Sat May 22 23:47:22 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964247, encodeId=3fd196424e63, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a671610372, createdName=Sarinai, createdTime=Mon May 10 11:06:46 CST 2021, time=2021-05-10, status=1, ipAttribution=)]
    2022-01-10 ms5000001146316601

    口服免疫是个难题

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1202660, encodeId=0f5b120266003, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Tue Mar 15 07:46:43 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182982, encodeId=b857118298203, content=口服免疫是个难题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be4f5437570, createdName=ms5000001146316601, createdTime=Mon Jan 10 22:18:22 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977024, encodeId=181a9e702476, content=快快快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5aec5112847, createdName=1461bde6m98暂无昵称, createdTime=Sat Jun 26 10:34:46 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967851, encodeId=95b796e85131, content=口服免疫疗法, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqhOK9Hy7pNdYtJHcetpYCa3iaoZ3lbGBPI4cg4t02cSn4vs01p4Ab2WRy1SFMRQ8fb26KlLia1TT9g/132, createdBy=c3de5238591, createdName=丁丁8399, createdTime=Sat May 22 23:47:22 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964247, encodeId=3fd196424e63, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a671610372, createdName=Sarinai, createdTime=Mon May 10 11:06:46 CST 2021, time=2021-05-10, status=1, ipAttribution=)]
    2021-06-26 1461bde6m98暂无昵称

    快快快

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1202660, encodeId=0f5b120266003, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Tue Mar 15 07:46:43 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182982, encodeId=b857118298203, content=口服免疫是个难题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be4f5437570, createdName=ms5000001146316601, createdTime=Mon Jan 10 22:18:22 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977024, encodeId=181a9e702476, content=快快快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5aec5112847, createdName=1461bde6m98暂无昵称, createdTime=Sat Jun 26 10:34:46 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967851, encodeId=95b796e85131, content=口服免疫疗法, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqhOK9Hy7pNdYtJHcetpYCa3iaoZ3lbGBPI4cg4t02cSn4vs01p4Ab2WRy1SFMRQ8fb26KlLia1TT9g/132, createdBy=c3de5238591, createdName=丁丁8399, createdTime=Sat May 22 23:47:22 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964247, encodeId=3fd196424e63, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a671610372, createdName=Sarinai, createdTime=Mon May 10 11:06:46 CST 2021, time=2021-05-10, status=1, ipAttribution=)]
    2021-05-22 丁丁8399

    口服免疫疗法

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1202660, encodeId=0f5b120266003, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Tue Mar 15 07:46:43 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182982, encodeId=b857118298203, content=口服免疫是个难题, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be4f5437570, createdName=ms5000001146316601, createdTime=Mon Jan 10 22:18:22 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977024, encodeId=181a9e702476, content=快快快, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5aec5112847, createdName=1461bde6m98暂无昵称, createdTime=Sat Jun 26 10:34:46 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967851, encodeId=95b796e85131, content=口服免疫疗法, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqhOK9Hy7pNdYtJHcetpYCa3iaoZ3lbGBPI4cg4t02cSn4vs01p4Ab2WRy1SFMRQ8fb26KlLia1TT9g/132, createdBy=c3de5238591, createdName=丁丁8399, createdTime=Sat May 22 23:47:22 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964247, encodeId=3fd196424e63, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a671610372, createdName=Sarinai, createdTime=Mon May 10 11:06:46 CST 2021, time=2021-05-10, status=1, ipAttribution=)]
    2021-05-10 Sarinai

    谢谢

    0